CLNN News and Press, Clene Inc. From 04/17/24

2024-04-17 06:55:40 ET DENVER, Colo., Apr 17, 2024 ( 247marketnews.com )- Clene Inc. (Nasdaq: CLNN ) presented Phase 2 VISIONARY-MS long term extension (LTE) study results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver. The improved clinical, functional, an...

2024-04-16 17:20:23 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene stock rallies 52% post-marke...

Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) Significantly improved clinical outcomes associated with long-term daily or...

Multiple sclerosis (MS) is a chronic illness that affects an individual’s central nervous system. The disease manifests differently in each individual and has varying trajectories, which makes it difficult to manage. It also has no cure. New research has identified three subtypes of the...

Clene (NASDAQ: CLNN) , alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. These include amyotrophic lateral sclerosis (“...

Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain’s bioenergetic metabolites, essentially “reversing the clock” on what would be considered healthy aging CNM-Au8 has shown promi...

The publication provides a comprehensive analysis of proteins from human blood plasma that interact with CNM-Au8(R) CNM-Au8 nanocrystals coated with a protein corona are less prone to clumping compared to those without any coating Certain apolipoproteins found on the nanocrystals' surface, wh...

2024-03-26 14:19:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we’re done here, right? Of course, human nature being what it is, people are ...

Clene’s recently released 2023 financial and operational updates highlight the company’s developments for the treatment of amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis CNM-Au8(R) functions as a neuroprotective and remyelinating therapy in neurodegener...

Recent research assessed the differences in Parkinson’s disease progression between research populations and real-world data. Parkinson’s disease is a progressive disorder that affects the nervous system and body parts controlled by the nerves. Illness-modifying treatments have...